DN-020198

Primary objective: To evaluate the safety and tolerability of DN020198 tablets in subjects with advanced solid tumors who have failed or are intolerant to standard treatment or who currently have no standard treatment, and to determine its maximum tolerated dose (MTD) and/or Phase II recommended dose (RP2D). Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of DN020198 tablets in subjects with advanced solid tumors who have failed or are intolerant to standard treatment or who currently have no standard treatment; to evaluate the preliminary efficacy of DN020198 tablets in subjects with advanced solid tumors who have failed or are intolerant to standard treatment or who currently have no standard treatment (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1). Exploratory objective: To evaluate the extent of immune response activated by DN020198 tablets and its correlation with preliminary efficacy.